Israeli biotechnology company Can-Fite BioPharma Ltd. CANF said Monday that its drug candidate Piclidenoson for the treatment of osteoarthritis in mammals has been granted Patent No. 10,265,337 from the U.S. Patent and Trademark Office with the title “Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment.”
The company is considering possible partnerships with companies from the animal health pharmaceutical industry that could in-license and create Piclidenoson for the companion animal market.
Canine osteoarthritis is being treated with oral non-steroidal anti-inflammatory drugs that only address symptoms and have damaging side effects, and an injectable disease modifying osteoarthritis drug which only affects the progression of the disease, according to the company.
Don’t miss out on the top cannabis stories of the day. Click here to sign up for our daily insider newsletter.
Piclidenoson, “a novel, first-in-class, A3 adenosine receptor agonist small molecule, orally bioavailable drug,” is said to offer safer and more effective oral treatment for canine osteoarthritis. It is also in Phase III trials for rheumatoid arthritis and psoriasis.
“As the number of companion animals increase and their role in family life becomes more prominent, the animal health market has shown robust growth. Piclidenoson may provide superior relief to companion animals for indications including canine osteoarthritis. While Can-Fite remains entirely focused on the development of Piclidenoson for rheumatoid arthritis and psoriasis indications, we do see an opportunity to out-license our drugs in the veterinary market,” CEO Dr. Pnina Fishman said in a statement.
Can-Fite BioPharma is a biotechnology company focused on treatments for cancer, sexual dysfunctions and inflammatory diseases.
The stock was trading 2.52% higher at $2.44 at the time of publication Monday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.